spacer
home > ebr > summer 2017 > upcycling genomics
PUBLICATIONS
European Biopharmaceutical Review

Upcycling Genomics

Gene therapies have taken centre stage in the medical field and interest is growing rapidly. For the first time, people can hope for a true cure of heritable disabilities by accessing a patient’s genome, as opposed to being treated only symptomatically, and any acquired pathologies with genetic elements are part of this development. HIV, for example, ‘hides’ in blood cells by integrating into the host’s genome, making it nearly impossible to remove from the system without genetic means. Asthma, arthritis, hypertension and many forms of cancers are in part caused by environmental factors that throw our genetic or epi-genetic makeup out of whack.

Of course, the application of genetic tools to patients is a controversial issue, and the backlash of early trials gone wrong in the 1990s severely dampened the whole, a setback that would be felt for over 10 years in the research community. With the number of clinical studies slumping and little growth for a decade, the concurrent rise of improved gene tools, paired with a much deeper understanding of the mechanisms underlying gene delivery, prepared a veritable rebirth of this field.

Following the rise of CRISPR/Cas9 technologies, the number of therapeutic strategies has become as plentiful as the range of human afflictions. This new shift towards gene therapy brings a measurable need for the optimisation of gene delivery strategies to enable practitioners to better transport their candidate constructs in a more targeted therapeutic context. While systemic applications favour the development of adeno-associated virus vector systems, highly efficient lentiviral vectors stand out as the system of choice for ex vivo therapies of hematopoietic cells (HCs) and hematopoietic stem cells (HSCs).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Franziska C Ruf is Senior Key Accounts Manager at SIRION Biotech with strong experience in molecular and cellular biology and her immunologic and hematopoietic background. Franziska worked as Project Coordinator and a Post-Doctoral Researcher in the Department of Hematology and Oncology at Klinikum rechts der Isar, Technical University Munich, Germany, where she also received her PhD in the Laboratory of Stem Cell Physiology.
spacer
Dr Franziska C Ruf
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioGenes Establishes Scientific Advisory Board

Berlin, Germany, December 12, 2017 / B3C newswire / -- BioGenes GmbH, specializing in ELISA development and production and a global leader in host cell protein (HCP) assay development, today announces the establishment of a Scientific Advisory Board which includes the following four renowned experts:
More info >>

White Papers

The Use of Stainless Steel Equipment Within Laboratories and Clean Rooms

Teknomek Ltd

Teknomek explains why stainless steel is the material of choice for laboratories and hygienic manufacturing.
More info >>

 
Industry Events

IRT Europe Summit

10-11 April 2018, The Hotel Brussels, Belgium

New clinical trial regulations are requiring sponsors to keep tighter oversight than ever before – from audit trails to tracking system changes – resulting in high costs and trial delays. IRT Europe explores implementation best practices and how interactive response technologies can be utilised to improve supply chain planning and optimise clinical trials.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement